B-cell antigen receptor signaling and autoimmunity

Contemporary Targeted Therapies in Rheumatology

Volumn , Issue , 2007, Pages 31-44

  Nutku Bilir, Esra ^a   Pugh Bernard, Aimee E ^a   Gauld, Stephen ^a   Merrell, Kevin ^a   Cambier, John C ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 60849108797     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (156)

1. Anolik J, Sanz I. B cells in human and murine systemic lupus erythematosus. Curr Opin Rheumatol 2004; 16(5): 505-12.
2. Lipsky PE. Systemic lupus erythematosus: An autoimmune disease of B cell hyperactivity. Nat Immunol2001; 2(9): 764-6.
3. Leslie D, Lipsky P, Notkins AL. Autoantibodies as predictors of disease. J Clin Invest 2001; 108(10): 1417-22.
4. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003; 48(6): 1484-92.
5. Edwards JC, Leandro MJ, Cambridge G. B lymphocyte depletion in rheumatoid arthritis: targeting of CD20. Curr Dir Autoimmun 2005; 8: 175-92.
6. Anolik JH, Barnard J, Cappione A et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50(11): 3580-90.
7. Press OW, Howell-Clark J, Anderson S, Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994; 83(5): 1390-7.
8. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83(2): 435-45.
9. Chan OT, Madaio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 1999; 169: 107-21.
10. Tian J, Zekzer D, Lu Y, Dang H, Kaufman DL. B cells are crucial for determinant spreading of T cell autoimmunity among beta cell antigens in diabetes-prone nonobese diabetic mice. J Immunol 2006; 176(4): 2654-61.
11. Looney RJ, Anolik J, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 2004; 16(3): 180-5.
12. Ferry H, Leung JC, Lewis G et al. B-cell tolerance. Transplantation 2006; 81(3): 308-15.
13. Wardemann H, Yurasov S, Schaefer A et al.Predominant autoantibody production by early human B cell precursors. Science 2003; 301(5638): 1374-7.
14. Teh YM, Neuberger MS. The immunoglobulin (Ig)alpha and Igbeta cytoplasmic domains are independently sufficient to signal B cell maturation and activation in transgenic mice. J Exp Med 1997; 185(10): 1753-8.
15. Pike KA, Ratcliffe MJ. Dual requirement for the Ig alpha immunoreceptor tyrosine-based activation motif (ITAM) and a conserved non-Ig alpha ITAM tyrosine in supporting Ig alpha beta-mediated B cell development. J Immunol 2005; 174(4): 2012-20.
16. Cambier JC. Antigen and Fc receptor signaling. The awesome power of the immunoreceptor tyrosine-based activation motif (ITAM). J Immunol 1995; 155(7): 3281-5.
17. Kurosaki T. [B cell signaling]. Nihon Rinsho Meneki Gakkai Kaishi 1999; 22(6): 378-81.[in Japanese]
18. Clark MR, Campbell KS, Kazlauskas A et al. The B cell antigen receptor complex: Association of Ig-alpha and Ig-beta with distinct cytoplasmic effectors. Science 1992; 258(5079): 123-6.
19. Reichlin A, Hu Y, Meffre E et al. B cell development is arrested at the immature B cell stage in mice carrying a mutation in the cytoplasmic domain of immunoglobulin beta. J Exp Med 2001; 193(1): 13-23.
20. Torres RM, Hafen K. A negative regulatory role for Ig-alpha during B cell development. Immunity 1999; 11(5): 527-36.
21. Flaswinkel H, Reth M. Dual role of the tyrosine activation motif of the Ig-alpha protein during signal transduction via the B cell antigen receptor. EMBO J 1994; 13(1): 83-9.
22. Kraus M, Saijo K, Torres RM, Rajewsky K. Ig-alpha cytoplasmic truncation renders immature B cells more sensitive to antigen contact. Immunity 1999; 11(5): 537-45.
23. Kraus M, Pao LI, Reichlin A et al. Interference with immunoglobulin (Ig)alpha immunoreceptor tyrosine-based activation motif (ITAM) phosphorylation modulates or blocks B cell development, depending on the availability of an Igbeta cytoplasmic tail. J Exp Med2001; 194(4): 455-69.
24. Pleiman CM, Abrams C, Gauen LT et al. Distinct p53/56lyn and p59fyn domains associate with non-phosphorylated and phosphorylated Ig-alpha. Proc Natl Acad Sci U S A 1994; 91(10): 4268-72.
25. Cheng PC, Brown BK, Song W, Pierce SK. Translocation of the B cell antigen receptor into lipid rafts reveals a novel step in signaling. J Immunol 2001; 166(6): 3693-701.
26. Kurosaki T, Johnson SA, Pao L et al. Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling. J Exp Med 1995; 182(6): 1815-23.
27. Rowley RB, Burkhardt AL, Chao HG, Matsueda GR, Bolen JB. Syk protein-tyrosine kinase is regulated by tyrosine-phosphorylated Ig alpha/Ig beta immunore-ceptor tyrosine activation motif binding and autophosphorylation. J Biol Chem 1995; 270(19): 11590-4.
28. Allman D, Lindsley RC, DeMuth W et al. Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J Immunol 2001; 167(12): 6834-40.
29. Khan WN, Sideras P, Rosen FS, Alt FW. The role of Bruton's tyrosine kinase in B-cell development and function in mice and man. Ann N Y Acad Sci 1995; 764: 27-38.
30. Chan VW, Meng F, Soriano P, DeFranco AL, Lowell CA. Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation. Immunity 1997; 7(1): 69-81.
31. Nishizumi H, Taniuchi I, Yamanashi Y et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity1995; 3(5): 549-60.
32. Turner M, Mee PJ, Costello PS et al. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature 1995; 378(6554): 298-302.
33. Xu Y, Harder KW, Huntington ND, Hibbs ML, Tarlinton DM. Lyn tyrosine kinase: Accentuating the positive and the negative. Immunity 2005; 22(1): 9-18.
34. Law DA, Chan VW, Datta SK, DeFranco AL. B-cell antigen receptor motifs have redundant signalling capabilities and bind the tyrosine kinases PTK72, Lyn and Fyn. Curr Biol 1993; 3(10): 645-57.
35. D'Ambrosio D, Hippen KL, Minskoff SA et al.Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by Fc gamma RIIB1. Science 1995; 268(5208): 293-7.
36. D'Ambrosio D, Fong DC, Cambier JC. The SHIP phosphatase becomes associated with Fc gammaRIIB1 and is tyrosine phosphorylated during 'negative' signaling. Immunol Lett 1996; 54(2-3): 77-82.
37. Nishizumi H, Horikawa K, Mlinaric-Rascan I, Yamamoto T. A double-edged kinase Lyn: A positive and negative regulator for antigen receptor-mediated signals. J Exp Med 1998; 187(8): 1343-8.
38. Hibbs ML, Tarlinton DM, Armes J et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995; 83(2): 301-11.
39. Du C, Sriram S. Increased severity of experimental allergic encephalomyelitis in lyn-/- mice in the absence of elevated proinflammatory cytokine response in the central nervous system. J Immunol 2002; 168(6): 3105-12.
40. Hibbs ML, Harder KW, Armes J et al. Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity. J Exp Med 2002; 196(12): 1593-604.
41. Takata M, Sabe H, Hata A et al. Tyrosine kinases Lyn and Syk regulate B cell receptor-coupled Ca2+ mobilization through distinct pathways. EMBO J 1994; 13(6): 1341-9.
42. Pao LI, Famiglietti SJ, Cambier JC. Asymmetrical phosphorylation and function of immunoreceptor tyrosine-based activation motif tyrosines in B cell antigen receptor signal transduction. J Immunol 1998; 160(7): 3305-14.
43. de Weers M, Brouns GS, Hinshelwood S et al. B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia. J Biol Chem 1994; 269(39): 23857-60.
44. Tsukada S, Saffran DC, Rawlings DJ et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993; 72(2): 279-90.
45. Conley ME. B cells in patients with X-linked agammaglobulinemia. J Immunol 1985; 134(5): 3070-4.
46. Rosen FS, Cooper MD, Wedgwood RJ. The primary immunodeficiencies. N Engl J Med 1995; 333(7): 431-40.
47. Rawlings DJ, Saffran DC, Tsukada S et al. Mutation of unique region of Bruton's tyrosine kinase in immunod-eficient XID mice. Science 1993; 261(5119): 358-61.
48. Thomas JD, Sideras P, Smith CI et al. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science 1993; 261(5119): 355-8.
49. Satterthwaite AB, Cheroutre H, Khan WN, Sideras P, Witte ON. Btk dosage determines sensitivity to B cell antigen receptor cross-linking. Proc Natl Acad Sci U S A1997; 94(24): 13152-7.
50. Ng YS, Wardemann H, Chelnis J, Cunningham-Rundles C, Meffre E. Bruton's tyrosine kinase is essential for human B cell tolerance. J Exp Med 2004; 200(7): 927-34.
51. Samuels J, Ng YS, Coupillaud C, Paget D, Meffre E. Human B cell tolerance and its failure in rheumatoid arthritis. Ann N Y Acad Sci 2005; 1062: 116-26.
52. Mahajan S, Ghosh S, Sudbeck EA et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide]. J Biol Chem 1999; 274(14): 9587-99.
53. Fu C, Turck CW, Kurosaki T, Chan AC. BLNK: A central linker protein in B cell activation. Immunity 1998; 9(1): 93-103.
54. Ishiai M, Kurosaki M, Pappu R et al. BLNK required for coupling Syk to PLC gamma 2 and Rac1-JNK in B cells. Immunity 1999; 10(1): 117-25.
55. Kurosaki T, Tsukada S. BLNK: connecting Syk and Btk to calcium signals. Immunity 2000; 12(1): 1-5.
56. Wienands J, Schweikert J, Wollscheid B et al. SLP-65: A new signaling component in B lymphocytes which requires expression of the antigen receptor for phosphorylation. J Exp Med 1998; 188(4): 791-5.
57. Goitsuka R, Fujimura Y, Mamada H et al. BASH, a novel signaling molecule preferentially expressed in B cells of the bursa of Fabricius. J Immunol 1998; 161(11): 5804-8.
58. Chiu CW, Dalton M, Ishiai M, Kurosaki T, Chan AC. BLNK: molecular scaffolding through 'cis'-mediated organization of signaling proteins. EMBO J 2002; 21(23): 6461-72.
59. Mizuno K, Tagawa Y, Mitomo K et al. Src homology region 2 (SH2) domain-containing phosphatase-1 dephosphorylates B cell linker protein/SH2 domain leukocyte protein of 65 kDa and selectively regulates c-Jun NH2-terminal kinase activation in B cells. J Immunol 2000; 165(3): 1344-51.
60. Jumaa H, Wollscheid B, Mitterer M et al. Abnormal development and function of B lymphocytes in mice deficient for the signaling adaptor protein SLP-65. Immunity 1999; 11(5): 547-54.
61. Niiro H, Maeda A, Kurosaki T, Clark EA. The B lymphocyte adaptor molecule of 32 kD (Bam32) regulates B cell antigen receptor signaling and cell survival. J Exp Med 2002; 195(1): 143-9.
62. Fournier E, Isakoff SJ, Ko K et al. The B cell SH2/PH domain-containing adaptor Bam32/DAPP1 is required for T cell-independent II antigen responses. Curr Biol2003; 13(21): 1858-66.
63. Han A, Saijo K, Mecklenbrauker I, Tarakhovsky A, Nussenzweig MC. Bam32 links the B cell receptor to ERK and JNK and mediates B cell proliferation but not survival. Immunity 2003; 19(4): 621-32.
64. Alessi DR, Downes CP. The role of PI 3-kinase in insulin action. Biochim Biophys Acta 1998; 1436(1-2): 151-64.
65. Andjelkovic M, Alessi DR, Meier R et al. Role of translocation in the activation and function of protein kinase B. J Biol Chem 1997; 272(50): 31515-24.
66. Takata M, Kurosaki T. A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2. J Exp Med 1996; 184(1): 31-40.
67. Brennan P, Mehl AM, Jones M, Rowe M. Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells. Oncogene 2002; 21(8): 1263-71.
68. Beckwith M, Fenton RG, Katona IM, Longo DL. Phosphatidylinositol-3-kinase activity is required for the anti-Ig-mediated growth inhibition of a human B-lymphoma cell line. Blood 1996; 87(1): 202-10.
69. Aagaard-Tillery KM, Jelinek DF. Phosphatidylinositol 3-kinase activation in normal human B lymphocytes. J Immunol 1996; 156(12): 4543-54.
70. Buhl AM, Cambier JC. Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton's tyrosine kinase. J Immunol 1999; 162(8): 4438-46.
71. Fruman DA, Snapper SB, Yballe CM et al. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science 1999; 283(5400): 393-7.
72. Ingham RJ, Holgado-Madruga M, Siu C, Wong AJ, Gold MR. The Gab1 protein is a docking site for multiple proteins involved in signaling by the B cell antigen receptor. J Biol Chem 1998; 273(46): 30630-7.
73. Suzuki H, Terauchi Y, Fujiwara M, et al. Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase. Science1999; 283(5400): 390-2.
74. Antony P, Petro JB, Carlesso G et al. B-cell antigen receptor activates transcription factors NFAT (nuclear factor of activated T-cells) and NF-kappaB (nuclear factor kappaB) via a mechanism that involves diacyl-glycerol. Biochem Soc Trans 2004; 32(Pt 1): 113-15.
75. Pham LV, Tamayo AT, Yoshimura LC, Lin-Lee YC, Ford RJ. Constitutive NF-kB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival. Blood 2005; 106(12): 3940-7.
76. Fu L, Lin-Lee YC, Pham LV et al. Constitutive NF-kB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood 2006; 107(11): 4540-8.
77. Dolmetsch RE, Lewis RS, Goodnow CC, Healy JI. Differential activation of transcription factors induced by Ca2+ response amplitude and duration. Nature1997; 386(6627): 855-8.
78. Saijo K, Mecklenbrauker I, Santana A et al. Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha. J Exp Med 2002; 195(12): 1647-52.
79. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol 2002; 20: 55-72.
80. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298(5600): 1911-12.
81. Hatta Y, Tsuchiya N, Ohashi J et al. Association of Fc gamma receptor IIIB, but not of Fc gamma receptor IIA and IIIA polymorphisms with systemic lupus erythematosus in Japanese. Genes Immun 1999; 1(1): 53-60.
82. Kyogoku C, Dijstelbloem HM, Tsuchiya N et al.Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum 2002; 46(5): 1242-54.
83. Floto RA, Clatworthy MR, Heilbronn KR et al. Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts. Nat Med2005; 11(10): 1056-8.
84. Blank MC, Stefanescu RN, Masuda E et al. Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus. Hum Genet 2005; 117(2-3): 220-7.
85. Prokunina L, Castillejo-Lopez C, Oberg F et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002; 32(4): 666-9.
86. Hatta Y, Tsuchiya N, Matsushita M et al. Identification of the gene variations in human CD22. Immunogenetics1999; 49(4): 280-6.
87. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000; 165(11): 6635-43.
88. Huck S, Le Corre R, Youinou P, Zouali M. Expression of B cell receptor-associated signaling molecules in human lupus. Autoimmunity 2001; 33(3): 213-24.
89. Cyster JG, Goodnow CC. Protein tyrosine phosphatase 1C negatively regulates antigen receptor signaling in B lymphocytes and determines thresholds for negative selection. Immunity 1995; 2(1): 13-24.
90. Shultz LD, Rajan TV, Greiner DL. Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency. Trends Biotechnol1997; 15(8): 302-7.
91. Nitschke L. The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr Opin Immunol2005; 17(3): 290-7.
92. Dal Porto JM, Gauld SB, Merrell KT et al. B cell antigen receptor signaling 101. Mol Immunol 2004; 41(6-7): 599-613.
93. Muta T, Kurosaki T, Misulovin Z et al. A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling. Nature 1994; 368(6466): 70-3.
94. Famiglietti SJ, Nakamura K, Cambier JC. Unique features of SHIP, SHP-1 and SHP-2 binding to FcgammaRIIb revealed by surface plasmon resonance analysis. Immunol Lett 1999; 68(1): 35-40.
95. Hippen KL, Buhl AM, D'Ambrosio D et al.Fc gammaRIIB1 inhibition of BCR-mediated phospho-inositide hydrolysis and Ca2+ mobilization is integrated by CD19 dephosphorylation. Immunity 1997; 7(1): 49-58.
96. Tamir I, Stolpa JC, Helgason CD et al. The RasGAP-binding protein p62dok is a mediator of inhibitory FcgammaRIIB signals in B cells. Immunity 2000; 12(3): 347-58.
97. Takai T, Nakamura A, Akiyama K. Fc receptors as potential targets for the treatment of allergy, autoimmune disease and cancer. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3(3): 187-97.
98. Bolland S, Ravetch JV. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 2000; 13(2): 277-85.
99. Davis RS, Dennis G Jr, Odom MR et al. Fc receptor homologs: newest members of a remarkably diverse Fc receptor gene family. Immunol Rev 2002; 190: 123-36.
100. Mechetina LV, Najakshin AM, Alabyev BY, Chikaev NA, Taranin AV. Identification of CD16-2, a novel mouse receptor homologous to CD16/Fc gamma RIII. Immunogenetics 2002; 54(7): 463-8.
101. Okazaki T, Otaka Y, Wang J et al. Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b-/-Pdcd1-/- mice. J Exp Med 2005; 202(12): 1643-8.
102. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A 2001; 98(24): 13866-71.
103. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motifcarrying immunoreceptor. Immunity 1999; 11(2): 141-51.
104. Hitomi Y, Tsuchiya N, Kawasaki A et al. CD72 polymorphisms associated with alternative splicing modify susceptibility to human systemic lupus erythematosus through epistatic interaction with FCGR2B. Hum Mol Genet 2004; 13(23): 2907-17.
105. Adachi T, Wakabayashi C, Nakayama T, Yakura H, Tsubata T. CD72 negatively regulates signaling through the antigen receptor of B cells. J Immunol2000; 164(3): 1223-9.
106. McGaha TL, Sorrentino B, Ravetch JV. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 2005; 307(5709): 590-3.
107. Bolland S, Yim YS, Tus K, Wakeland EK, Ravetch JV. Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-/-) mice. J Exp Med 2002; 195(9): 1167-74.
108. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19: 275-90.
109. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6(4): 443-6.
110. Doody GM, Justement LB, Delibrias CC et al. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science 1995; 269(5221): 242-4.
111. Chen J, McLean PA, Neel BG et al. CD22 attenuates calcium signaling by potentiating plasma membrane calcium-ATPase activity. Nat Immunol 2004; 5(6): 651-7.
112. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Hyperresponsive B cells in CD22-deficient mice. Science 1996; 274(5288): 798-801.
113. Nitschke L, Carsetti R, Ocker B, Kohler G, Lamers MC. CD22 is a negative regulator of B-cell receptor signalling. Curr Biol 1997; 7(2): 133-43.
114. Gerlach J, Ghosh S, Jumaa H et al. B cell defects in SLP65/BLNK-deficient mice can be partially corrected by the absence of CD22, an inhibitory coreceptor for BCR signaling. Eur J Immunol 2003; 33(12): 3418-26.
115. Samardzic T, Marinkovic D, Danzer CP et al.Reduction of marginal zone B cells in CD22-deficient mice. Eur J Immunol 2002; 32(2): 561-7.
116. Morel L, Mohan C, Yu Y et al. Functional dissection of systemic lupus erythematosus using congenic mouse strains. J Immunol 1997; 158(12): 6019-28.
117. Mohan C, Morel L, Yang P, Wakeland EK. Genetic dissection of systemic lupus erythematosus pathogenesis: Sle2 on murine chromosome 4 leads to B cell hyperactivity. J Immunol 1997; 159(1): 454-65.
118. Kelm S, Schauer R, Manuguerra JC, Gross HJ, Crocker PR. Modifications of cell surface sialic acids modulate cell adhesion mediated by sialoadhesin and CD22. Glycoconj J 1994; 11(6): 576-85.
119. Powell LD, Jain RK, Matta KL, Sabesan S, Varki A. Characterization of sialyloligosaccharide binding by recombinant soluble and native cell-associated CD22. Evidence for a minimal structural recognition motif and the potential importance of multisite binding. J Biol Chem 1995; 270(13): 7523-32.
120. Poe JC, Fujimoto Y, Hasegawa M et al. CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nat Immunol 2004; 5(10): 1078-87.
121. Lajaunias F, Ida A, Kikuchi S et al. Differential control of CD22 ligand expression on B and T lymphocytes, and enhanced expression in murine systemic lupus. Arthritis Rheum 2003; 48(6): 1612-21.
122. Jin L, McLean PA, Neel BG, Wortis HH. Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signaling. J Exp Med 2002; 195(9): 1199-205.
123. Kelm S, Gerlach J, Brossmer R, Danzer CP, Nitschke L. The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound. J Exp Med 2002; 195(9): 1207-13.
124. Collins BE, Smith BA, Bengtson P, Paulson JC. Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling. Nat Immunol 2006; 7(2): 199-206.
125. Ghosh S, Bandulet C, Nitschke L. Regulation of B cell development and B cell signalling by CD22 and its ligands a2,6-linked sialic acids. Int Immunol 2006; 18(4): 603-11.
126. Sgroi D, Varki A, Braesch-Andersen S, Stamenkovic I. CD22, a B cell-specific immunoglobulin superfamily member, is a sialic acid-binding lectin. J Biol Chem1993; 268(10): 7011-18.
127. Law CL, Aruffo A, Chandran KA, Doty RT, Clark EA. Ig domains 1 and 2 of murine CD22 constitute the ligand-binding domain and bind multiple sialylated ligands expressed on B and T cells. J Immunol 1995; 155(7): 3368-76.
128. Han S, Collins BE, Bengtson P, Paulson JC. Homomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking. Nat Chem Biol 2005; 1(2): 93-7.
129. Zhang M, Varki A. Cell surface sialic acids do not affect primary CD22 interactions with CD45 and surface IgM nor the rate of constitutive CD22 endocytosis. Glycobiology 2004; 14(11): 939-49.
130. Domer T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical study of epratuzumab (humanized anti-CD22 antibody). Arthritis Res. Ther. 2006; 8(3): R74.
131. Kung C, Pingel JT, Heikinheimo M et al. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nat Med2000; 6(3): 343-5.
132. Justement LB, Campbell KS, Chien NC, Cambier JC. Regulation of B cell antigen receptor signal transduction and phosphorylation by CD45. Science 1991; 252(5014): 1839-42.
133. Hermiston ML, Xu Z, Weiss A. CD45: A critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 2003; 21: 107-37.
134. Hata A, Sabe H, Kurosaki T, Takata M, Hanafusa H. Functional analysis of Csk in signal transduction through the B-cell antigen receptor. Mol Cell Biol 1994; 14(11): 7306-13.
135. Gupta N, DeFranco AL. Visualizing lipid raft dynamics and early signaling events during antigen receptor-mediated B-lymphocyte activation. Mol Biol Cell 2003; 14(2): 432-44.
136. Majeti R, Bilwes AM, Noel JP, Hunter T, Weiss A. Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge. Science 1998; 279(5347): 88-91.
137. Majeti R, Xu Z, Parslow TG et al. An inactivating point mutation in the inhibitory wedge of CD45 causes lym-phoproliferation and autoimmunity. Cell 2000; 103(7): 1059-70.
138. Hermiston ML, Tan AL, Gupta VA, Majeti R, Weiss A. The juxtamembrane wedge negatively regulates CD45 function in B cells. Immunity 2005; 23(6): 635-47.
139. Hayami K, Fukuta D, Nishikawa Y et al. Molecular cloning of a novel murine cell-surface glycoprotein homologous to killer cell inhibitory receptors. J Biol Chem 1997; 272(11): 7320-7.
140. Kubagawa H, Burrows PD, Cooper MD. A novel pair of immunoglobulin-like receptors expressed by B cells and myeloid cells. Proc Natl Acad Sci U S A 1997; 94(10): 5261-6.
141. Maeda A, Scharenberg AM, Tsukada S et al. Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1. Oncogene 1999; 18(14): 2291-7.
142. Maeda A, Kurosaki M, Kurosaki T. Paired immunoglobulin-like receptor (PIR)-A is involved in activating mast cells through its association with Fc receptor gamma chain. J Exp Med 1998; 188(5): 991-5.
143. Blery M, Kubagawa H, Chen CC et al. The paired Ig-like receptor PIR-B is an inhibitory receptor that recruits the protein-tyrosine phosphatase SHP-1. Proc Natl Acad Sci U S A 1998; 95(5): 2446-51.
144. Ho LH, Uehara T, Chen CC, Kubagawa H, Cooper MD. Constitutive tyrosine phosphorylation of the inhibitory paired Ig-like receptor PIR-B. Proc Natl Acad Sci U S A 1999; 96(26): 15086-90.
145. Yotsumoto K, Okoshi Y, Shibuya K et al. Paired activating and inhibitory immunoglobulin-like receptors, MAIR-I and MAIR-II, regulate mast cell and macrophage activation. J Exp Med 2003; 198(2): 223-33.
146. Nemazee D. Antigen receptor 'capacity' and the sensitivity of self-tolerance. Immunol Today 1996; 17(1): 25-9.
147. Casellas R, Shih TA, Kleinewietfeld M et al.Contribution of receptor editing to the antibody repertoire. Science 2001; 291(5508): 1541-4.
148. Pelanda R, Schwers S, Sonoda E et al. Receptor editing in a transgenic mouse model: site, efficiency, and role in B cell tolerance and antibody diversification. Immunity 1997; 7(6): 765-75.
149. Gauld SB, Benschop RJ, Merrell KT, Cambier JC. Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat Immunol 2005; 6(11): 1160-7.
150. Cooke MP, Heath AW, Shokat KM et al.Immunoglobulin signal transduction guides the specificity of B cell-T cell interactions and is blocked in tolerant self-reactive B cells. J Exp Med 1994; 179(2): 425-38.
151. Rathmell JC, Goodnow CC. The in vivo balance between B cell clonal expansion and elimination is regulated by CD95 both on B cells and in their microenvironment. Immunol Cell Biol 1998; 76(5): 387-94.
152. Vilen BJ, Burke KM, Sleater M, Cambier JC. Transmodulation of BCR signaling by transduction-incompetent antigen receptors: implications for impaired signaling in anergic B cells. J Immunol 2002; 168(9): 4344-51.
153. Vilen BJ, Nakamura T, Cambier JC. Antigen-stimulated dissociation of BCR mIg from Ig-alpha/Ig-beta: implications for receptor desensitization. Immunity1999; 10(2): 239-48.
154. Parent BA, Wang X, Song W. Stability of the B cell antigen receptor modulates its signaling and antigentargeting functions. Eur J Immunol 2002; 32(7): 1839-46.
155. Benschop RJ, Brandl E, Chan AC, Cambier JC. Unique signaling properties of B cell antigen receptor in mature and immature B cells: implications for tolerance and activation. J Immunol 2001; 167(8): 4172-9.
156. Healy JI, Dolmetsch RE, Timmerman LA et al.Different nuclear signals are activated by the B cell receptor during positive versus negative signaling. Immunity 1997; 6(4): 419-28.